Environmental and Social Data Sheet

Overview

Project Name: RYVU (EGFF)
Project Number: 20210357
Country: Poland
Project Description: The project will cover R&D activities, both OPEX and CAPEX related to clinical state development programmes (incl. clinical trials, regulatory process, IP) as well as further discoveries and pre-clinical pipeline.

EIA required: no
Project included in Carbon Footprint Exercise¹: no

Environmental and Social Assessment

Environmental Assessment

The project’s activities are not listed in any of the annexes of the EU Directive 2014/52/EU amending 2011/92/EU. The proposed RDI activities will take place at existing RDI facilities already authorised for similar activities, and have no significant environmental impact on the surroundings. The costs are mostly covering OPEX (eg personnel) and CAPEX (new and specialised equipment) to perform the high-end research and development activities.

The promoter’s practices are in compliance with the relevant national and EU regulations (directives 2001/83/EC, 2005/28/EC, 2001/20/EC and applicable good practice quality guidelines and regulations. These RDI activities are considered climate neutral, and as such are in line with the Paris Alignment criteria as set out in the EIB’s CBR (Climate Bank Roadmap).

Social Assessment, where applicable

- Gender equality

The project will generate positions accessible to highly qualified RDI workers in Krakow, Poland, which would provide increased access to social and economic benefits. The promoter is an equal opportunity employer, committed to gender equality, with an active program for promoting women in science.

¹ Only projects that meet the scope of the Carbon Footprint Exercise, as defined in the EIB Carbon Footprint Methodologies, are included, provided estimated emissions exceed the methodology thresholds: 20,000 tonnes CO2e/year absolute (gross) or 20,000 tonnes CO2e/year relative (net) – both increases and savings.
Other Environmental and Social Aspects
Through the RDI activities and investments, the promoter expects to increase its current level of highly skilled personnel, while contributing to European scientific innovation, hence fostering and nurturing the vital research community.

The promoter is committed to animal welfare and the responsible use of animals for scientific purposes. Moreover, the promoter complies with the European Directive 2010/63/EU on the protection of animals used for scientific purposes, where applicable.

Conclusions and Recommendations
The project concerns investments in research and development in human health products that will be carried out in existing facilities without changing their already authorised scope. RDI activities are not listed under the Annex I or II of the EIA Directive, and as such the EIA process is not triggered. The research activities undertaken in the project are aimed at delivering novel and improved medicinal products with a positive impact on healthcare. Therefore, the project, if successful, is expected to bring positive social impact.

Considering the above, the project is acceptable for Bank financing in terms of environmental and social aspects.